HKG:2157

2 stories mentioning HKG:2157Updated just now

Every FINWIRES story that references HKG:2157, newest first.

What's the latest news on HKG:2157?

Lepu Biopharma to Present Four Cancer Drug Trial Results at Oncology Conference

Lepu Biopharma (HKG:2157) said positive results from four studies have been selected for presentations at the 2026 European Society for Medical Oncology (ESMO) Congress.The ESMO Congress will be held in Madrid, Spain, from October 23 to 27, 2026, a Wednesday bourse filing showed.The trials tested CMG901 for the treatment of gastroesophageal carcinoma, MRG007 for colorectal cancer, MRG003 and HX008 for head and neck squamous cell carcinoma, and the same drug combination for thyroid cancer.

HKG:2157

Asia57d ago

Lepu Biopharma, AstraZeneca Cancer Drug Meets Phase 3 Survival Goal

Lepu Biopharma (HKG:2157) said antibody-drug conjugate CMG901 (AZD0901) met the primary overall survival endpoint in a global Phase 3 trial in patients with Claudin 18.2-positive advanced gastric and related cancers.The drug, which is being developed and commercialized globally by AstraZeneca under a 2023 licensing agreement, also met a key secondary endpoint of overall survival in the broader second-line and later treatment population, according to a Tuesday Hong Kong bourse filing.The progression-free survival endpoint showed improvement but did not reach statistical significance. The company said the drug's safety profile was consistent with previous studies, with no new safety signals identified.

HKG:2157

Track with the FINWIRES app suite

FolioX

Track HKG:2157 in your portfolio

WheelAI

Analyze HKG:2157 options with the wheel strategy

StockInsider

See market sentiment on HKG:2157